Bromocriptine and CF 25-397 in the Treatment of Tardive Dyskinesia
Authors:
- Carol A. TammingaCTCarol A. Tamminga
- Thomas N. ChaseTCThomas N. Chase
- 1 April 1980
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 37 (4) , 204-205
Abstract
• Dopamine agonist therapy using se lected drugs at particular dosage levels has been found to have therapeutic benefit in certain dyskinetic syndromes. Two ergot derivatives with dopamine agonist properties were administered at relatively low doses to eight neuroleptic-free schizophrenic patients with tardive dyskinesia. Neither agent significantly improved dyskinetic symptoms; no symptoms worsened. Dopamine agonists likely vary in their selective activation of functionally distinct dopamine receptors.Keywords
This publication has 8 references indexed in Scilit:
- EFFECTS OF DOPAMINE AGONISTS ON DOPAMINERGIC UNIT ACTIVITY1979
- Multiple receptors for dopamineNature, 1979
- Lergotrile and lisuride: In vivo dopaminergic agonists which do not stimulate the presynaptic dopamine autoreceptorLife Sciences, 1978
- Multiple classes of dopamine receptors in mammalian central nervous system: The involvement of dopamine-sensitive adenylyl cyclaseLife Sciences, 1978
- Paradoxical response to dopamine agonists in tardive dyskinesiaAmerican Journal of Psychiatry, 1977
- Paradoxical Suppression of Chorea by ApomorphineJAMA, 1974
- Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activityJournal of Pharmacy and Pharmacology, 1972
- Dyskinesia and NeurolepticsArchives of General Psychiatry, 1968